Illumina Share Price (NASDAQ: ILMN)

$99.15

▲

-0.39

(-0.39%)

Last updated on August 29, 2025 at 1:29 am IST

$₹

Check the interactive Illumina Stock chart to analyse performance

Illumina stock performance

as on August 29, 2025 at 1:29 am IST

Today's Low:$97.86
Today's High:$99.28
$99.15
1.3%
Downside
Day's Volatility :1.43%
Upside
0.13%
52 Weeks Low:$68.70
52 Weeks High:$156.66
$99.15
30.71%
Downside
52 Weeks Volatility :56.15%
Upside
36.71%

Illumina Stock Returns

Period	Illumina Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	21.04%	3.5%	0.0%
6 Months	12.17%	-8.0%	0.0%
1 Year	-25.59%	-12.3%	0.0%
3 Years	-51.5%	8.4%	-6.1%

Illumina Inc. Key Stats

Check Illumina key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$99.54
Open	$99.28
Today's High	$99.28
Today's Low	$97.86
Market Capitalization	$15.8B
Today's Volume	$1.2M
52 Week High	$156.66
52 Week Low	$68.7
Revenue TTM	$4.3B
EBITDA	$1.1B
Earnings Per Share (EPS)	$7.9
PE Ratio	12.6
Profit Margin	29.34%
Quarterly Earnings Growth YOY	-0.96%
Return On Equity TTM	68.06%

Stock Returns calculator for Illumina Stock including INR - Dollar returns

The Illumina stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Illumina investment value today

Current value as on today

₹78,670

Returns

₹21,330

(-21.33%)

Returns from Illumina Stock

₹25,886 (-25.89%)

Dollar Returns*

₹4,556 (+4.56%)

Indian investors sentiment towards Illumina Stock

-8%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Illumina Stock from India on INDmoney has decreased by -8% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Illumina Stock

Name	Shares Held	Change in Shares	% of Assets
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	247	0.00	0.13%
DSP Healthcare Fund Direct Growth	160400	4465.54	4.52%

Global Institutional Holdings in Illumina Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
12.19%
Capital World Investors
10.83%
Vanguard Group Inc
9.86%
State Street Corp
3.81%
WCM Investment Management
2.88%
Loomis, Sayles & Company LP
2.75%

Analyst Recommendation on Illumina Stock

Rating

Trend

Buy

46%Buy

43%Hold

10%Sell

Based on 30 Wall street analysts offering stock ratings for Illumina(by analysts ranked 0 to 5 stars)

Illumina Share Price Target

What analysts predicted

Upside of 13.01%

Target:

$112.05

Current:

$99.15

Illumina share price target is $112.05, a slight Upside of 13.01% compared to current price of $99.15 as per analysts' prediction.

Illumina Stock Insights

Price Movement
In the last 1 month, ILMN stock has moved down by -8.4%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.04B → 1.05B (in $), with an average increase of 1.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 131.0M → 235.0M (in $), with an average increase of 44.3% per quarter
ILMN vs IDXX (1 yr)
In the last 1 year, Idexx Laboratories, Inc. has given 31.5% return, outperforming this stock by 57.1%
ILMN vs IDXX (3 yr)
In the last 3 years, Idexx Laboratories, Inc. has given 83.6% return, outperforming this stock by 136.2%
Price to Sales
ForILMN every $1 of sales, investors are willing to pay $3.7, whereas for Idexx Laboratories, Inc., the investors are paying $13.0 for every $1 of sales.

Illumina Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$3.5B	↑ 6.3%
Net Income	$1.0B	↑ 21.31%
Net Profit Margin	28.28%	↑ 3.5%

	FY20	Y/Y Change
Revenue	$3.2B	↓ 8.58%
Net Income	$656.0M	↓ 34.53%
Net Profit Margin	20.25%	↓ 8.03%

	FY21	Y/Y Change
Revenue	$4.5B	↑ 39.73%
Net Income	$762.0M	↑ 16.16%
Net Profit Margin	16.84%	↓ 3.41%

	FY22	Y/Y Change
Revenue	$4.6B	↑ 1.28%
Net Income	$-4.4B	↓ 677.95%
Net Profit Margin	-96.07%	↓ 112.91%

	FY23	Y/Y Change
Revenue	$4.5B	↓ 1.75%
Net Income	$-1.2B	↓ 73.64%
Net Profit Margin	-25.78%	↑ 70.29%

	FY24	Y/Y Change
Revenue	$4.4B	↓ 2.93%
Net Income	$-1.2B	↑ 5.34%
Net Profit Margin	-27.97%	↓ 2.19%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$1.1B	↓ 4.1%
Net Income	$-126.0M	↓ 28.41%
Net Profit Margin	-11.71%	↑ 3.98%

	Q2 FY24	Q/Q Change
Revenue	$1.1B	↑ 3.35%
Net Income	$-2.0B	↑ 1477.78%
Net Profit Margin	-178.78%	↓ 167.07%

	Q3 FY24	Q/Q Change
Revenue	$1.1B	↓ 2.88%
Net Income	$705.0M	↓ 135.46%
Net Profit Margin	65.28%	↑ 244.06%

	Q4 FY24	Q/Q Change
Revenue	$1.1B	↑ 2.22%
Net Income	$187.0M	↓ 73.48%
Net Profit Margin	16.94%	↓ 48.34%

	Q1 FY25	Q/Q Change
Revenue	$1.0B	↓ 5.71%
Net Income	$131.0M	↓ 29.95%
Net Profit Margin	12.58%	↓ 4.36%

	Q2 FY25	Q/Q Change
Revenue	$1.1B	↑ 1.73%
Net Income	$235.0M	↑ 79.39%
Net Profit Margin	22.19%	↑ 9.61%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$2.5B	↑ 7.26%

	FY20	Y/Y Change
Profit	$2.2B	↓ 10.7%

	FY21	Y/Y Change
Profit	$3.2B	↑ 43.17%

	FY22	Y/Y Change
Profit	$3.0B	↓ 5.77%

	FY23	Y/Y Change
Profit	$2.7B	↓ 7.67%

	FY24	Y/Y Change
Profit	$2.9B	↑ 4.26%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$667.0M	↓ 1.19%

	Q2 FY24	Q/Q Change
Profit	$721.0M	↑ 8.1%

	Q3 FY24	Q/Q Change
Profit	$745.0M	↑ 3.33%

	Q4 FY24	Q/Q Change
Profit	$728.0M	↓ 2.28%

	Q1 FY25	Q/Q Change
Profit	$683.0M	↓ 6.18%

	Q2 FY25	Q/Q Change
Profit	$695.0M	↑ 1.76%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$1.1B	↓ 7.97%
Investing Cash Flow	$745.0M	↓ 141.09%
Financing Cash Flow	$-897.0M	↓ 251.01%

	FY20	Y/Y Change
Operating Cash Flow	$1.1B	↑ 2.76%
Investing Cash Flow	$-554.0M	↓ 174.36%
Financing Cash Flow	$-766.0M	↓ 14.6%

	FY21	Y/Y Change
Operating Cash Flow	$545.0M	↓ 49.54%
Investing Cash Flow	$-1.1B	↑ 92.96%
Financing Cash Flow	$-51.0M	↓ 93.34%

	FY22	Y/Y Change
Operating Cash Flow	$392.0M	↓ 28.07%
Investing Cash Flow	$-591.0M	↓ 44.71%
Financing Cash Flow	$1000.0M	↓ 2060.78%

	FY23	Y/Y Change
Operating Cash Flow	$478.0M	↑ 21.94%
Investing Cash Flow	$-231.0M	↓ 60.91%
Financing Cash Flow	$-1.2B	↓ 221.0%

	FY24	Y/Y Change
Operating Cash Flow	$837.0M	↑ 75.1%
Investing Cash Flow	$-178.0M	↓ 22.94%
Financing Cash Flow	$-570.0M	↓ 52.89%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$77.0M	↓ 65.47%
Investing Cash Flow	$-48.0M	↓ 43.53%
Financing Cash Flow	$35.0M	↓ 234.62%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$80.0M	↑ 3.9%
Investing Cash Flow	$-41.0M	↓ 14.58%
Financing Cash Flow	$-226.0M	↓ 745.71%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$316.0M	↑ 295.0%
Investing Cash Flow	$-41.0M	↑ 0.0%
Financing Cash Flow	$-332.0M	↑ 46.9%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$364.0M	↑ 15.19%
Investing Cash Flow	$-48.0M	↑ 17.07%
Financing Cash Flow	$-47.0M	↓ 85.84%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$240.0M	↓ 34.07%
Investing Cash Flow	$-63.0M	↑ 31.25%
Financing Cash Flow	$-195.0M	↑ 314.89%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$234.0M	↓ 2.5%
Investing Cash Flow	$-49.0M	↓ 22.22%
Financing Cash Flow	$-371.0M	↑ 90.26%

Illumina Technicals Summary

Sell

Neutral

Buy

Illumina is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Illumina Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Illumina Inc.	-8.44%	12.17%	-25.59%	-51.5%	-72.13%
Agilent Technologies Inc.	0.54%	-7.22%	-16.73%	-7.48%	18.19%
Idexx Laboratories, Inc.	12.02%	46.61%	31.52%	83.71%	63.88%
Thermo Fisher Scientific, Inc.	2.27%	-7.72%	-20.2%	-11.94%	13.79%
Danaher Corp.	0.5%	-1.33%	-23.23%	-25.01%	-0.71%
Iqvia Holdings Inc.	-1.43%	0.0%	-24.72%	-12.59%	15.3%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Illumina Inc.	12.6	12.6	0.62	4.51	0.68	0.09	NA	14.66
Agilent Technologies Inc.	29.23	29.23	1.74	5.58	0.19	0.08	0.01	21.61
Idexx Laboratories, Inc.	53.52	53.52	4.8	12.6	0.65	0.23	NA	18.2
Thermo Fisher Scientific, Inc.	28.28	28.28	1.99	22.49	0.13	0.05	0.0	133.77
Danaher Corp.	43.88	43.88	2.07	7.77	0.07	0.04	0.01	73.1
Iqvia Holdings Inc.	27.4	27.4	1.08	11.87	0.2	0.05	NA	33.99

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Illumina Inc.	Buy	$15.8B	-72.13%	12.6	29.34%
Agilent Technologies Inc.	Buy	$33.7B	18.19%	29.23	17.59%
Idexx Laboratories, Inc.	Buy	$51.3B	63.88%	53.52	24.41%
Thermo Fisher Scientific, Inc.	Buy	$184.5B	13.79%	28.28	15.24%
Danaher Corp.	Buy	$147.7B	-0.71%	43.88	14.21%
Iqvia Holdings Inc.	Buy	$32.1B	15.3%	27.4	7.88%

About Illumina Inc.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Organization	Illumina
Employees	8970
CEO	Mr. Jacob Thaysen Ph.D.
Industry	Health Technology

Key Management of Illumina Inc.

Name	Title
Mr. Jacob Thaysen Ph.D.	CEO & Director
Mr. Ankur Dhingra CPA	Chief Financial Officer
Mr. Kevin Carl Pegels	Chief of Global Operations
Dr. Steven Barnard Ph.D.	Chief Technology Officer
Stephanie Campos	President
Mr. Scott Ericksen	VP & Chief Accounting Officer
Mr. Mark Field	Chief Information Officer
Mr. Brian Blanchett	VP of Finance & Treasurer and Interim Head of Investor Relations
Mr. Scott Davies	Chief Legal Officer
Mr. Jakob Wedel	Chief Strategy & Corporate Development Officer

Important FAQs about investing in ILMN Stock from India :

What is Illumina share price today?

Illumina share price today is $99.15 as on August 29, 2025 at 1:29 am IST at the close of the market. Illumina share today touched a day high of $99.28 and a low of $97.86.

What is the 52 week high and 52 week low for Illumina share?

Illumina share touched a 52 week high of $156.66 and a 52 week low of $68.70. Illumina stock price today i.e. August 29, 2025 at 1:29 am IST is closed at $99.15, lower by 36.71% versus the 52 week high.

How to invest in Illumina Stock (ILMN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Illumina on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Illumina Shares that will get you 0.0151 shares as per Illumina share price of $99.15 per share as on August 29, 2025 at 1:29 am IST.

What is the minimum amount required to buy Illumina Stock (ILMN) from India?

Indian investors can start investing in Illumina (ILMN) shares with as little as ₹87.6463 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹876.46 in Illumina stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Illumina share’s latest price of $99.15 as on August 29, 2025 at 1:29 am IST, you will get 0.1009 shares of Illumina. Learn more about fractional shares .

What are the returns that Illumina has given to Indian investors in the last 5 years?

Illumina stock has given -72.13% share price returns and 19.64% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?